Center for Cancer Immunology and Immunotherapy at University of Louisville
Official title: Center for Cancer Immunology and Immunotherapy (CCII)
Funded at University of Louisville · NIH-11399778 · Data updated 2026-11-12
A cancer-immunology center at the University of Louisville is renewing support to advance tumor immunology research and train the next generation of scientists to use the immune system to fight cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | February 1, 2020 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,312,893 |
| NIH project number | 5P20GM135004-07 |
| Project ID | NIH-11399778 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced cancer may benefit from future immunotherapy advances arising from this program.
✕Less likely to help
Early-stage basic research may not immediately translate to patient therapies for all conditions.
What this research studies
This grant funds a COBRE center focused on basic cancer immunology and translational work to develop immunotherapies. It supports multidisciplinary research, training, and career development to build a pipeline of immunology experts. The program leverages prior successes in publications and NIH/DOD funding to push toward innovative, patient-relevant immunotherapy approaches. It also strengthens resources, mentorship, and pilot projects to accelerate discoveries that could improve cancer care. The renewal emphasizes expanding translational efforts and sustaining a robust research and training ecosystem at UofL.
Why it matters
Potential benefit: If successful, patients with advanced cancer could benefit from new immunotherapy strategies and faster development of effective treatments.
How similar studies have gone: Previous COBRE programs have produced productive researchers and funded projects, with continued expansion in Phase 2.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Yan, Jun — University of Louisville
- Study coordinator: Yan, Jun
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.